Full-Time

SR. Research Associate/Associate Scientist

Nonclinical Development

Adicet Bio

Adicet Bio

51-200 employees

Off-the-shelf gamma delta T therapies

Compensation Overview

$108k - $150k/yr

+ Annual Bonus + Equity + ESPP + 401(k) Match

San Carlos, CA, USA

In Person

Onsite at least three days per week (Tuesday–Thursday) required.

Bachelor's, Master's

Category
Biology & Biotech (1)

Get referred to Adicet Bio

See people who can refer or advise you

Requirements
  • Bachelor’s degree in biological sciences or a related field with 5+ years of relevant R&D experience, or a Master’s degree with 3+ years of experience, preferably in immuno-oncology, within an industry setting.
  • Significant experience designing, executing, analyzing, and interpreting in vivo studies using murine xenograft disease models and/or humanized immunology models.
  • Demonstrated proficiency administering therapeutic agents and establishing xenograft models through intravenous, intraperitoneal, and subcutaneous routes in mice.
  • Strong technical proficiency in blood collection, including submandibular and tail-vein sampling, as well as tissue necropsy and sample processing for flow-cytometry applications.
  • Experience with aseptic mammalian cell culture, including the maintenance and preparation of human cancer cell lines for nonclinical in vivo studies.
  • Hands-on experience with in vivo bioluminescence and/or fluorescence imaging, including image acquisition and data analysis using IVIS platforms.
  • Experience with laboratory techniques such as flow cytometry, ELISA, qPCR/ddPCR, and cytokine bead-based assays is preferred.
  • Excellent organizational, communication, data-analysis, and technical-documentation skills.
  • Demonstrated ability to work independently, troubleshoot scientific and technical challenges, and contribute innovative solutions.
  • Ability to manage multiple priorities and thrive in a fast-paced, collaborative, and supportive research environment.
  • Onsite presence at least three days per week (Tuesday–Thursday mandatory), with some roles requiring full-time onsite presence.
Responsibilities
  • Coordinate and execute in vivo and ex vivo nonclinical studies to evaluate Adicet’s immune-cell and gene-therapy platforms, including efficacy, pharmacokinetic/pharmacodynamic, and safety assessments in relevant murine oncology and immunology models.
  • Contribute to study design, experimental planning, timeline development, and data-driven decision-making to support program advancement.
  • Collaborate and communicate effectively with cross-functional teams and external contract research organizations to coordinate study execution, troubleshoot technical challenges, and ensure study endpoints align with program objectives
  • Perform necropsies and process tissues for downstream analyses, including flow cytometry, qPCR/ddPCR, and ELISA, to characterize pharmacologic activity and elucidate mechanisms of action.
  • Maintain accurate, complete, and well-organized experimental records in accordance with internal documentation and quality standards.

Adicet Bio develops cancer immunotherapies using donor-derived, allogeneic gamma delta T cells that are engineered to target and kill cancer cells. The therapy uses off-the-shelf cells instead of a patient’s own cells, making treatment faster and potentially more readily available. The product works by introducing these modified T cells into a patient, where they seek out and destroy tumor cells. Adicet Bio differentiates itself by providing an immediately available, genetically modified immune cell therapy rather than patient-specific treatments, and by focusing on gamma delta T cells, which may offer targeted anti-tumor activity with a different safety and efficacy profile. The company aims to bring these therapies to patients through commercialization, licensing, and partnerships with healthcare providers and larger pharma companies, supported by ongoing research and development and strategic initiatives like the merger with resTORbio and a substantial funding round.

Company Size

51-200

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2014

Get referred to Adicet Bio

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 5, 2026 cash was $118.2 million, funding operations into 2H 2027.
  • Q3 2026 prula-cel data should cover 22 lupus patients with 12-month follow-up.
  • ADI-212 filing is planned for Q3 2026, opening a new PSMA oncology path.

What critics are saying

  • August 3, 2026 CMO Julie Maltzman resigned; interim coverage weakens clinical execution.
  • July 2025 ADI-270 shutdown and 30% layoffs exposed brittle pipeline concentration.
  • If prula-cel stalls in 2H 2026, Adicet faces another dilutive financing cycle.

What makes Adicet Bio unique

  • Adicet’s prula-cel uses allogeneic gamma delta T cells, not patient-specific manufacturing.
  • January 7, 2026 FDA alignment enabled outpatient prula-cel dosing in lupus patients.
  • MaxCyte’s August 4, 2025 platform license supports Adicet’s gene-edited manufacturing and scale.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Paid Vacation

Paid Sick Leave

Paid Holidays

Parental Leave

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

3%
BioSpace
Jul 22nd, 2026
Adicet Bio to participate in fireside chat at Canaccord Genuity 46th Annual Growth Conference.

Adicet Bio to participate in fireside chat at Canaccord Genuity 46th Annual Growth Conference. July 22, 2026 | REDWOOD CITY, Calif.-(BUSINESS WIRE)-Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference being held from August 11-13, 2026, in Boston. Details of the event are as follows: Date: Tuesday, August 11, 2026 Time: 10:30 a.m. ET The live audio webcast can be accessed on the Investors section of Adicet Bio's website at https://www.adicetbio.com. An archived replay will be available for 30 days following the presentation. About Adicet Bio, Inc. Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com. Adicet Bio, Inc. Investor and Media Contacts Anne Bowdidge [email protected] Penelope Belnap Precision AQ [email protected]

Adicet Bio
Jul 21st, 2026
Adicet Bio to participate in fireside chat at Canaccord Genuity 46th Annual Growth Conference.

Adicet Bio to participate in fireside chat at Canaccord Genuity 46th Annual Growth Conference. REDWOOD CITY, Calif.-(BUSINESS WIRE)-Jul. 21, 2026- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference being held from August 11-13, 2026, in Boston. Details of the event are as follows: Date: Tuesday, August 11, 2026 Time: 10:30 a.m. ET The live audio webcast can be accessed on the Investors section of Adicet Bio's website at https://www.adicetbio.com. An archived replay will be available for 30 days following the presentation. About Adicet Bio, Inc. Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit its website at https://www.adicetbio.com. Adicet Bio, Inc. Investor and Media Contacts Anne Bowdidge [email protected] Penelope Belnap Precision AQ [email protected]

TipRanks
Jan 7th, 2026
Adicet Bio doubles prula-cel Phase 1 enrolment, extends cash runway to 2027 with $75M raise

Adicet Bio has expanded enrollment in its Phase 1 prula-cel programme for autoimmune diseases to over 20 patients as of 31 December 2025, more than doubling since October. All seven autoimmune cohorts are now actively enrolling, including the first ANCA-associated vasculitis patient. The company has secured FDA alignment for outpatient dosing of lupus nephritis and systemic lupus erythematosus patients. Adicet is also advancing ADI-212 for metastatic castration-resistant prostate cancer, targeting a regulatory filing in the first half of 2026. An October 2025 equity raise of approximately $74.8 million has extended the company's cash runway into the second half of 2027. Multiple clinical data updates are planned throughout 2026 as Adicet works towards a pivotal trial design.

Investing.com
Oct 7th, 2025
Adicet Bio $80M Stock Offering Announced

Adicet Bio (NASDAQ:ACET) announced an $80 million stock offering, pricing 70,001,000 shares at $1 each and pre-funded warrants for 10 million shares at $0.9999. The offering, expected to close by October 8, 2025, aims to bolster finances amid rapid cash burn. Jefferies and Guggenheim Securities are joint book-running managers. Adicet also reported positive results from its ADI-001 trial and halted ADI-270 development, reducing its workforce by 30% to extend cash reserves into Q4 2026.

BioProcess International
Aug 13th, 2025
Auspicious alliance: MaxCyte and Adicet partner to develop off-the-shelf T-cell therapies

Auspicious alliance: MaxCyte and Adicet partner to develop off-the-shelf T-cell therapies.